Neurona Therapeutics presents positive clinical update on NRTX-1001 cell therapy trial in drug-resistant epilepsy
- NRTX-1001 cell therapy shows promising results in reducing seizures in drug-resistant epilepsy patients.
- Low dose cohort achieved a 92% median reduction in seizures, with 80% of subjects reporting over 75% reduction.
- High dose cohort showed a 78% median reduction in seizures, with 60% of subjects reporting over 75% reduction.
- FDA granted RMAT designation; pivotal trial planned for the second half of 2025.
Read more
Rapport Therapeutics presents data on seizure biomarker association
- A 30% reduction in long episodes correlates with a 50% or greater reduction in clinical seizures.
- The ongoing Phase 2a trial for RAP-219 in focal epilepsy uses long episode frequency as the primary endpoint.
- Additional studies support RAP-219's potential as a transformative treatment for focal epilepsy.
- Topline data from the Phase 2a trial is expected in mid-2025.
Read more
Stoke Therapeutics presents new open-label extension study data for zorevunersen in Dravet syndrome
- Stoke Therapeutics shared data from Phase 1/2a and open-label extension studies of zorevunersen, showing significant seizure reduction in Dravet syndrome patients.
- Patients treated with zorevunersen experienced an 87% median reduction in convulsive seizures at month eight of the OLE study.
- Continuous improvements in cognition and behavior were observed over two years of treatment.
- Zorevunersen was generally well-tolerated, with most adverse events being unrelated to the study drug.
Read more
SK Life Science presents data on XCOPRI at AES 2024
- SK Life Science showcased data on XCOPRI (cenobamate tablets) at the AES 2024 Annual Meeting.
- The data provided insights into cenobamate's dual mechanism of action, enhancing GABAergic inhibition and reducing neuronal excitability.
- A study showed significant reduction in epileptiform events and clinically reported seizures with cenobamate treatment.
- The potential for flexible and individualized dosing was highlighted, aiding in optimal seizure reduction.
Read more
